|
|
FOR IMMEDIATE RELEASE
Contact: Ronald Trahan, APR, Ronald Trahan Associates Inc.
508-359-4005, x108
Pico-Tesla expands operations to Midwest region
New facility in Novi (Detroit), Mich., complements sites
in Littleton, Colo., and Clearwater, Fla.
“We are excited to work with Pico-Tesla to explore the clinical
potential that Magneceutical® Therapy may offer to Parkinson’s
patients,” said Max Rashed, COO, Detroit Clinical Research Center,
“and we look forward to working closely with the Company’s
research related to other disease states, including
Alzheimer’s disease, fibromyalgia, and osteoarthritis.”
LITTLETON, Colo., Aug. 26, 2010 —Pico-Tesla, The Magneceutical® Company, announced
today that it has expanded its operations by opening a facility in N ovi, Mich., which is
approximately 30 miles northwest of Detroit. The address and phone number are: 27780 Novi
Road, Suite 100, Novi, MI 48377; 248-773-8969. The Company is headquartered in Littleton,
Colo., and also has operations in Clearwater, Fla.
“Expansion of our company to the Detroit area allows Pico-Tesla to ramp-up patient enrollment
for our ongoing Phase III clinical study of Magneceutical® Therapy in Parkinson’s disease
patients,” said Allen Braswell, CEO of Pico-Tesla. “The addition of Detroit and Clearwater gives
us three clinics that are now involved in our pivotal trial in Parkinson’s Disease. With IRB
approval in hand, we look forward to commencing patient enrollment in the Detroit area, with the
help of the Detroit Clinical Research Center (DCRC), a well-known CRO (clinical research
organization) in the Midwest.”
The purpose of the ongoing Phase III clinical trial is to demonstrate the efficacy of
Magneceutical® Therapy as an adjunctive therapy to improving aspects of health and quality of
life that are relevant to patients with Parkinson's Disease. Pico-Tesla intends to submit the Phase
III data and analysis via a 510(k) de novo application to obtain FDA clearance to sell the device
in the United States. The Phase III clinical trial was designed by principal investigator Rajeev
Kumar, M.D., a movement disorder specialist and medical director of the Colorado
Neurological Institute Movement Disorder Center, Englewood, Colo.
Pico-Tesla’s Magneceutical® Therapy involves the use of an extremely low-level
electromagnetic field (EMF) applied by a specially designed device—the Resonator™, invented
by Dr. Jerry I. Jacobson, along with proprietary therapeutic protocols—intended to improve
a number of the signs and symptoms of Parkinson’s and other diseases, including atrial
fibrillation, Alzheimer’s disease, fibromyalgia and osteoarthritis.
Privately held Pico-Tesla Magnetic Therapies is an emerging medical technology company with
operations at: 7852 South Elati, Suite #202, Littleton, CO 80120 (303-795-3222); and, 4700
140th Avenue North, Suite #101, Clearwater, FL 33762.
CAUTION: The Resonator™ device is an Investigational Device limited by federal (or United States) law
to investigational use. The Resonator™ device is not for sale, nor is the Magneceutical® Therapy generally
available outside of Investigational Review Board (IRB)-approved clinical studies.
|
